Antihypertensive drugs

Application &#945-Cyclodextrin can be used: In fabricating reversible supramolecular assemblies. As a modifier to enhance the solubility of oleic acid stabilized nanoparticles.

Application &#945-Cyclodextrin can be used: In fabricating reversible supramolecular assemblies. As a modifier to enhance the solubility of oleic acid stabilized nanoparticles.

Application &#945-Cyclodextrin can be used: In fabricating reversible supramolecular assemblies. As a modifier to enhance the solubility of oleic acid stabilized nanoparticles.

Application Intended for use in the Sigma &#945-Butyrate Esterase kit, procedure 181B Packaging 2.4g/L alpha-naphthyl butyrate in methanol solution with stabilizers

A903 WILSON WRAP CLR BLK FRM TSR AND ANTIFOG

A potent inhibitor of VEGF receptors, inhibiting VEGFR1, 2, and 3 with IC₅₀ values of 130, 23, and 18 nM, respectively orally bioavailable in vivo, blocking VEGF-induced angiogenesis and preventing the growth of primary tumors and

Acasunlimab (anti-4-1BB&PD-L1) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab (anti-4-1BB&PD-L1) enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 i

Acasunlimab (anti-4-1BB&PD-L1) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab (anti-4-1BB&PD-L1) enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 i

Acasunlimab (anti-4-1BB&PD-L1) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab (anti-4-1BB&PD-L1) enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 i

Acasunlimab (anti-4-1BB&PD-L1) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab (anti-4-1BB&PD-L1) enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 i

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the